Personnel Moves Archives - Page 40 of 42

BD CEO Polen to also serve as board chair

BD CEO Tom Polen

Tom Polen, the CEO of Becton Dickinson (NYSE:BDX), will also serve as BD’s board chair effective April 28, the company said today.

Polen takes over the board chair slot from former CEO Vincent A. Forlenza, who will retire at that time.

Polen, 47, has held the corner office at BD since January 2020. He joined the Franklin Lakes, N.J.–based company in 1999, rising through the ranks over the years.

“In Tom’s first year as CEO, he faced unprecedented challenges from the global COVID-19 pandemic, and successfully guided the company to assist in the pandemic while also advancing the focus and commitment to quality and compliance across the organization,” said Marshall Larsen, lead director for the BD board.

“Under his leadership, BD developed and rapidly scaled COVID-19 diagnostic testing, increased manufacturing for syringes and needles to meet the needs for worldwide COVID-19 vaccination campaigns and ens…

Butterfly Network names new CEO before going public via merger

Butterfly Network announced today that it named Dr. Todd Fruchterman as its new president & CEO, effective Feb. 1.

Fruchterman is set to take over for outgoing CEO Laurent Faracci, who stepped down this past weekend. Fruchterman assumes the role in advance of the closing of Butterfly Network’s announced merger with Longview Acquisition Corp., after which the combined business will go public.

“We are very excited Todd has joined Butterfly as president and CEO to lead the company at this critical stage. Todd brings together his unique qualifications and experience as an M.D., Ph.D. and proven business executive in public medical device companies, where he has successfully scaled disruptive technologies throughout his entire career,” Butterfly founder & chairman Dr. Jonathan Rothberg said in a news release. “Our most valuable assets are the people of Butterfly who innovate and serve on a daily basis, and I am pleased to support Todd…

Inogen names new CEO

Inogen (NSDQ:INGN) announced that it appointed Nabil Shabshab to serve as its new CEO, effective on Feb. 8, 2021.

Additionally, according to a news release, on Jan. 22, Inogen’s board appointed Shabshab to serve as a Class II director of the company, effective Feb. 8, too. His term will expire at the annual meeting of stockholders to be held in 2022.

Shabshab is set to succeed former CEO Scott Wilkinson, who announced his upcoming retirement as president, CEO and director in June. Wilkinson’s retirement is effective Feb. 8.

A veteran of the industry, Shabshab most recently served as worldwide president of diabetes care & digital health at Becton Dickinson since August 2017. Before that, from 2011, he was BD’s chief marketing officer and executive VP of strategic planning.

Prior to BD, Shabshab was executive VP, global portfolio, chief marketing officer and head of RD&E at Diversey, a cleaning…

Laura Francis to move up to CEO spot at Si-Bone

Laura Francis, soon-to-be CEO of Si-Bone

Si-Bone (NSDQ:SIBN) will promote its present CFO and COO Laura Francis into the corner office of the company, which makes the iFuse implant for treating lower back pain.

Francis will become CEO once the company finds a new CFO or May 1 — whatever comes first. Present CEO Jeff Dunn will stay with the company as executive chair.

“Laura has been an exemplary leader and operator for Si-Bone since joining the Company in 2015. She is an exceptional executive who is passionate about our mission. She is highly respected by investors and our team as well as our board of directors. She is committed to our principles and values and knows how to lead and execute our strategy to invest in future growth,” Dunn said in a news release out today.

Francis said it’s a period of unique opportunity for Si-Bone — which is also promoting its CCO Tony Recupero to the position of president, commercial operations, in charge of worldw…

NeuroOne Medical appoints new CFO

NeuroOne Medical Technologies (OTC:NMTC) announced today that it appointed Ronald McClurg as its chief financial officer.

McClurg, a veteran of 30 years in the space of financial leadership, has held the role of CFO for companies including Orthomet, Incisive Surgical, Video Sentry and Insignia Systems, having begun his career in public accounting at Ernst and Young, according to a news release.

“Over the past quarter, the company has made great progress in achieving key milestones and building our infrastructure,” NeuroOne president & CEO Dave Rosa said in the release. “With our future goal to uplist to a major national securities exchange, it became critical to add a seasoned senior financial executive such as Ron.

“His broad experience with both public and private companies as well as his familiarity with medical device companies make him an ideal fit for the role of CFO at NeuroOne. We are very fortunate to have him as part…

Orthofix names new global extremities president

Orthofix (NSDQ:OFIX) announced that it appointed Paul Gonsalves as the president of its global extremities business.

Gonsalves joins Lewisville, Texas-based Orthofix after previously serving as chief commercial officer at Integra LifeSciences (NSDQ:IART). He also served as senior VP of enterprise sales and corporate marketing at the medtech company.

Before his roles at Integra, Gonsalves served as senior VP and chief transformation officer with AccentCare and held the role of VP and GM of primary care at Novartis (NYSE:NVS), among a series of other roles including a handful at General Electric Healthcare (NYSE:GE).

In his new role, Gonsalves will also serve on the company’s executive leadership team while reporting to Orthofix president and CEO Jon Serbousek.

“Paul brings to Orthofix more than 30 years of industry experience and proven leadership that will both complement and strengthen our exceptional extremities management team,” Serbousek…

Varian names new president & COO among other personnel changes

Varian Medical Systems (NYSE:VAR) today announced a trio of personnel changes including the appointment of a new president and COO.

Effective Oct. 5, 2020, current Varian Oncology Systems president Chris Toth will take over the newly created roll of president and COO. As a result, current senior VP of global operations Kevin O’Reilly will take over as president of Varian Oncology Systems and VP of revenue operations Stephanie Foster will become senior VP of global supply chain operations.

“This announcement is a testament to the deep and diverse bench of talented leaders we have at Varian, as well as a reflection of our commitment to realizing our vision and strengthening our support for Varian’s customers and their patients,” Varian CEO Dow Wilson said in a news release. “I’m thrilled to congratulate Chris, Kevin and Stephanie on their expanded leadership roles, and I’m confident that they will ensure our entire team is well-positioned to build on Varian…

NextPhase Medical Devices appoints new CCO

NextPhase Medical Devices announced today that it appointed Robert Olsen to its newly created role of chief commercial officer.

Olsen’s responsibilities within the role include commercialization, leading sales, marketing and value streams, overseeing revenue and profit growth and ensuring customer satisfaction for the Waldwick, N.J.-based medical device contract manufacturer, according to a news release.

A veteran of more than 30 years in the medical device contract manufacturing space, Olsen has spent the past three years with NextPhase Medical Devices, having previously served as senior VP of business development. He also held sales, business development and leadership roles at companies such as Vention Medical, Flex and Nypro.

“We are fortunate to have a leader with Rob’s industry experience and passion for excellence,” NextPhase Medical Devices president & CEO Carlo Colesanti said in the release.“Over the last 3 years, he has been a great s…

Bardy Diagnostics names new CEO

BardyDx Carnation Ambulatory Monitor (CAM™) – P-wave centric™ ambulatory cardiac patch monitoring and arrhythmia detection

Bardy Diagnostics announced that it appointed Kevin Hykes as its new president, CEO and member of its board effective Aug. 31, 2020.

Hykes has more than 28 years of experience in the medical device industry, having served as president and CEO of Relievant Medical Systems, Metavention and Cameron Health. Additionally, Hykes held roles as an operating partner at Revival Healthcare Capital and Versant Ventures, having previously held leadership positions at Medtronic, too.

His role includes responsibilities for leading the development and execution of short-term and long-term business and financial strategies while managing the overall operations of Bardy, according to a news release.

“I’m very excited and pleased to have Kevin join our executive team as Pr…

Titan Medical CFO retires; succesor named

Titan Medical (TSX:TMD;OTC:TITFX) announced today that CFO Stephen Randall will retire and Monique Delorme will assume the role.

Randall has spent more than 10 years with Titan Medical, leading the company through 30 capital transactions and raising more than $260 million to fund research and development for its surgical robotic technologies, according to a news release.

“For the past 10 years, Stephen has played a pivotal role in Titan’s journey from an early-stage startup to become a leader in single-port robotic surgical technologies,” Titan Medical CEO David McNally said in the release. “Stephen’s leadership, guidance and unwavering commitment to Titan has been vital to our business – and for that we thank him.

“I am also pleased that Stephen will remain with the company in his capacity as a director of the board and will continue to guide the company toward realizing its vision for improving patient outcomes with its single-port robotic …

LensGen closes $10 million in bridge financing

LensGen’s Juvene IOL (Image from LensGen)

Intraocular lens developer LensGen announced today that it closed the addition of $10 million in a $20 million bridge financing.

HOYA Group’s corporate investment arm led the financing, which is part of a larger Series B round planned for early 2021 that is earmarked for funding the company through the approval of a pivotal FDA study for its Juvene fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, according to a news release.

“We are delighted to attract additional investment from an experienced ophthalmology and corporate strategic investor like HOYA in order to advance into the pivotal stage of our FDA clinical study and bring to market an innovative and elegant solution for treating cataracts and presbyopia,” LensGen founder & CEO Ramgopal Rao said in the release.

Irvine, Calif.-based LensGen also a…

BD names IR director

Becton Dickinson (NYSE:BDX) announced yesterday that it appointed Kristen Stewart as its new senior VP of strategy and investor relations.

In the newly created position, Stewart is slated to work closely with the BD executive team to “drive shareholder value and communicate the company’s long-term growth strategy,” according to a news release.

Stewart previously held roles at multiple Wall Street investment banks over two decades, most recently leading the medical technology research franchise at Barclays Capital. Institutional Investor has named her as one of the top three analysts in the medical supplies & devices category several times, BD said.

“I have watched through the analyst lens as BD has transformed into a global medical technology innovator,” Stewart said in the release. “I am excited by BD’s current strategic direction and believe the company has significant potential to optimize shareholder valu…